Ariphrenz Tablets
PDF Leaflet Revision Date: 21 February 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of schizophrenia and acute manic episodes in Bipolar I disorder.
Dosage (summary)
Starting dose: 10-15 mg/day; Maintenance: 15 mg/day; Max: 30 mg/day.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Safety in pregnancy not established; excreted in breast milk.
Key Drug Interactions
- CYP3A4 inhibitors
- CYP2D6 inhibitors
- CYP3A4 inducers
Contraindications
- Hypersensitivity to aripiprazole
- Children under 18
Common side effects
- Akathisia
- Nausea
- Sedation
- Dizziness
- Constipation
Counselling Points
- Monitor for suicidal thoughts
- Avoid alcohol
- Caution with driving
Serious warnings
- Risk of suicide
- Neuroleptic Malignant Syndrome
- Tardive dyskinesia
Important Disclaimer
The Ariphrenz Tablets professional information leaflet below is the property of Ascend Laboratories and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
